This is research, not a buy or sell recommendation. Robo-advice in Taiwan requires an FSC licence; FEAF analyses, explains and monitors, and the investor makes the decision. Judgement thresholds are working rules pending review by the team's finance members.
Plain-language summary of valuation, growth, profitability, balance sheet, and recent MOPS filings.
Mixed picture: 2 strengths against 2 watch-outs. Weigh them against your own goals.
Points to watch for a moderate profile: see the items marked above.
In plain words
Stock 4155 presents a P/E ratio of 8.63, which is well below the Biotechnology and medical median of 15.31. While revenue fell -6.8% in 2025, Q3 2026 revenue grew 49.0% year on year alongside a return on equity of 10.2%, a 14.6% net margin, and liabilities at 39.3% of total assets. Conversely, free cash flow was negative at -82 NT$ million in 2025, and recent alerts include board approval of new Vice Presidents as well as 1 filing waiting for human review. Ultimately, all final investment decisions rest entirely with the investor.
Written by gemini-3.6-flash from the facts above; every number was checked against them.
Strengths
+P/E 8.63 is well below the Biotechnology and medical median of 15.31 (38 listed peers): priced cheaper than peers. source (Key Stats) →
+Liabilities are only 39.3% of total assets (Q3 2026): a light debt load. source (Financials) →
Watch-outs
!Revenue fell -6.8% in 2025; latest quarter Q3 2026: 49.0% year on year. source (Financials) →
!Free cash flow was negative in 2025: -82 NT$ million, so spending exceeded operating cash. source (Financials) →
What to check before deciding
?Is the revenue decline temporary or structural?
?What is the spending for, and when does it start paying back?
What the analysis found
+Valuation vs peersP/E 8.63 is well below the Biotechnology and medical median of 15.31 (38 listed peers): priced cheaper than peers. source →
!GrowthRevenue fell -6.8% in 2025; latest quarter Q3 2026: 49.0% year on year. source →
·ProfitabilityReturn on equity 10.2% with a 14.6% net margin: moderate profitability. source →
+DebtLiabilities are only 39.3% of total assets (Q3 2026): a light debt load. source →
!Cash flowFree cash flow was negative in 2025: -82 NT$ million, so spending exceeded operating cash. source →
·Filings2 verified alert(s); latest on 2026-11-13: 本公司董事會通過新任業務處副總經理及管理處副總經理案 source →
·Filings1 filing(s) are held or rejected and wait for human review. source →